Clinical trial NCT04265170: Evaluating Blast-X® in Combination With Negative Pressure Wound Therapy
Official title: A Multicentre Pilot Clinical Trial, Evaluating Blast-X® in Combination With Negative Pressure Wound Therapy (NPWT, VAC®) in Validating 4-Week Wound Area Reduction and Reducing Bacterial Bioburden in Chronic Pressure Ulcers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pressure Ulcer
Lead sponsor: SerenaGroup, Inc.
Sponsor class: NETWORK
Collaborators: name: Next Science TM
First posted: 2020-02-11
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A Multi-center, Prospective Clinical Trial Evaluating the Combination of BlastX and Negative Pressure Wound Therapy (VAC).To evaluate the 4-week healing trajectory/wound area reduction with BlastX/VAC as compared with historical pre-study 4-week healing trajectory data and data from the US Wound Registry.

Detailed description: The study is a prospective, clinical trial designed to evaluate the combination of BlastX™ and VAC® in facilitating healing and reduction in bio-burden in pressure ulcers. After consenting, the ulcers of eligible subjects are treated with BlastX. After a 5 minute dwell time the wound VAC® is applied as per manufacturers guidelines. The subjects return to the center three times per week for dressing changes and application of BlastX. The duration of the trial is four weeks. Subjects undergo study procedures (biopsy for quantitative tissue culture, photography, fluorescence imaging and swabbing for protease testing) on a weekly basis. The standard of care for pressure ulcers will be continued including debridement, off-loading, and nutritional supplementation when appropriate.

Eligibility criteria: Inclusion Criteria:

1. Adult patients with a Full Thickness Pressure Ulcer Stage 3 through Stage 4 without exposed bone of greater than or equal to one month in duration located on the trunk (Sacral, trochanteric, ischial or posterior heel).
2. A signed and dated informed consent form.
3. Subject is able to comply with instructions and scheduled visits.
4. Ulcer surface area \>2cm2 and \< 100cm2.
5. The patient is a candidate for negative pressure wound therapy.

Exclusion Criteria:

1.Subject or caregiver is unable to manage VAC®device OR the patient cannot return for VAC dressing changes OR the patient does not qualify for home health visits. 2.Subject has major uncontrolled medical disorders such as serious cardiovascular, renal, liver or pulmonary disease, lupus, palliative care or sickle cell anemia.

3.Subject currently being treated for an active malignant disease or subjects with history of malignancy within the wound.

4.The Subject has other concurrent conditions that in the opinion of the Investigator may compromise subject safety.

5.Known contraindications to VAC® or Blast-X® 6.Known allergies to any of the Blast-X®components 7.Concurrent participation in another clinical trial that involves an investigation drug or device that would interfere with this study.

8.Subject is pregnant or breast feeding. 9.Subjects with a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within one month prior to first Screening Visit, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.

10.Index ulcer has been previously treated with tissue engineered materials (e.g. Apligraf® or Dermagraft®) or other scaffold materials (e.g. Oasis, Matristem) within the last 30 days preceding the first treatment visit.

11.Mini-nutritional assessment Malnutrition Indication score \<17. 12.Patient does not have adequate 4-week historical data on comparison in change of wound measurements, photos, costs and supplies used.

Primary outcomes:
measure: Wound reduction in surface area
timeFrame: 4 week
Secondary outcomes:
measure: Wounds have a reduction in bacterial load
timeFrame: 4 weeks
measure: Wounds have a reduction in inflammatory proteases
timeFrame: 4 weeks
measure: Reduction in wound-related pain
timeFrame: 4 weeks
measure: Incidence of device-related adverse events
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Kittanning
country: United States
facility: Armstrong County Memorial Hospital
state: Pennsylvania
Study officials:
References: